Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. Does it work? Listen and find out!
As many people know, my talks are big on repeated images: a (borrowed) ven diagram to explain how the elements of evidence based practice combine in true informed consent*; a heart to remind people that with all we do it is about ’empathy first’ ; a pause button to embed the idea, the ethic really, of reflective practice. I’ve no talent for well rendered art – rather, I hope that the beauty of this is that maybe my use of crudely sketched stick figures is less intimidating and , I hope, conveys useful ideas.
Still, it is wonderful to learn about the growing field of graphic medicine, where people far more skilled are building a community with a mission to leverage the advantages of comics in health care. A central figure, Dr. Ian Williams, recently published the graphic novel Bad Doctor. It is both intimate and accessible, defining of the genre.
See my quick review: http://www.amazon.com/review/R3DGN76DGTOGF0.
And please let me know if my own graphics are of use – see my first graphic novella, Love & Potions, about a young couple, both with autism, seeing a psychiatrist. It’s posted, free of course, on circlestretch.com.
You Might Also Enjoy...
Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. Does it work? Listen and find out!
ADHD is one of the most treatable conditions in psychiatry if patients adhere to medication regimens. So, why are parents so resistant to stimulant medications and how can we approach these misconceptions?
Each year in the US, there are about 1.04 million divorces, affecting about 800,000 children. How can we navigate the complexities of treating a child with divorce?
Do antipsychotics have neurotoxic effects in youth? In this episode, we’ll be banging the drum of caution about antipsychotic use in children and adolescents.
With a growing body of evidence supporting its clinical efficacy and cost-effectiveness relative to traditional ABA approaches, the developmental model is being used with increasing prevalence across the US.
Prescribing Psychotropics bridges the gap between the complexities of drug pharmacokinetics and everyday clinical practice, providing clinicians more insight into how psychiatric drugs behave (or misbehave!) once their patients take them.